Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel

Solithera's efficacy profile appears strong, but FDA has safety concerns, particularly its structural similarities to the controversial Ketek.

Cempra Inc. will have to convince FDA's Antimicrobial Drugs Advisory Committee to recommend approval for its macrolide antibiotic Solithera (solithromycin) in spite of serious liver safety concerns raised by the agency. The advisory committee will convene Nov. 4 to determine whether the efficacy results of the community-acquired bacterial pneumonia (CABP) treatment outweigh its risks, including hepatotoxicity.

Solithera was pitted against the approved antibiotic moxifloxacin in two randomized, double-blind, noninferiority Phase III trials. Moxifloxacin was chosen as...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers